Expression of the microRNA-200 Family, microRNA-205, and Markers of Epithelial-Mesenchymal Transition as Predictors for Endoscopic Submucosal Dissection over Esophagectomy in Esophageal Adenocarcinoma: A Single-Center Experience.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
20 02 2020
Historique:
received: 12 12 2019
revised: 13 02 2020
accepted: 14 02 2020
entrez: 26 2 2020
pubmed: 26 2 2020
medline: 20 2 2021
Statut: epublish

Résumé

Endoscopic submucosal dissection (ESD) is an effective treatment of early esophageal adenocarcinomas (EACs). The decision of ESD over esophagectomy is based on clinical evaluation of tumor depth and invasion. On a molecular level, tumor invasion is strongly associated with epithelial-to-mesenchymal transition (EMT). Here, we investigated whether localized ESD-resected and surgically resected EAC samples displayed different expression profiles of EMT protein and microRNA markers and whether these different expression profiles were able to retrospectively discriminate localized and surgically resected samples. By doing this, we aimed to evaluate whether preoperative measurement of EMT marker expression might support the decision regarding ESD over surgery. The results showed that ESD-resected samples displayed an epithelial expression profile, i.e., high expression of epithelial protein markers, whereas surgically resected samples displayed high expression of mesenchymal markers. In addition, the anti-EMT microRNA-205 was significantly more expressed in ESD-resected samples, whereas we found no significant differences in the expression levels of microRNA-200 family members. Furthermore, in our retrospective approach, we have demonstrated that measurement of selected EMT markers and microRNA-205 has significant discrimination power to distinguish ESD-resected and surgically resected samples. We suggest that the assessment of EMT status of EAC samples on a molecular level may support clinical evaluation regarding the applicability of ESD.

Identifiants

pubmed: 32093260
pii: cells9020486
doi: 10.3390/cells9020486
pmc: PMC7072807
pii:
doi:

Substances chimiques

Antigens, CD 0
CDH1 protein, human 0
Cadherins 0
Claudin-1 0
MIRN200 microRNA, human 0
MIRN205 microRNA, human 0
MicroRNAs 0
VIM protein, human 0
Vimentin 0
ZEB1 protein, human 0
Zinc Finger E-box-Binding Homeobox 1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Am J Gastroenterol. 2008 Jun;103(6):1340-5
pubmed: 18510606
Clin Cancer Res. 2011 May 1;17(9):3029-38
pubmed: 21248297
Gastrointest Endosc. 2004 Nov;60(5):703-10
pubmed: 15557945
Gut. 2007 Nov;56(11):1625-34
pubmed: 17938435
Dev Cell. 2008 Jun;14(6):818-29
pubmed: 18539112
Genes Dev. 2008 Apr 1;22(7):894-907
pubmed: 18381893
World J Gastroenterol. 2014 May 14;20(18):5540-7
pubmed: 24833885
Wideochir Inne Tech Maloinwazyjne. 2014 Jun;9(2):125-30
pubmed: 25097676
Nat Cell Biol. 2008 May;10(5):593-601
pubmed: 18376396
Oncotarget. 2018 Jan 11;9(8):8179-8196
pubmed: 29487725
Carcinogenesis. 2015 May;36(5):521-7
pubmed: 25784377
J Clin Pathol. 2015 Jul;68(7):529-35
pubmed: 25855799
Oncol Lett. 2012 May;3(5):1059-1063
pubmed: 22783391
Lancet. 2017 Nov 25;390(10110):2383-2396
pubmed: 28648400
Dig Endosc. 2013 Mar;25 Suppl 1:29-38
pubmed: 23368404
Exp Mol Pathol. 2015 Jun;98(3):411-8
pubmed: 25746664
PLoS One. 2016 May 18;11(5):e0155754
pubmed: 27191723
Cancer Prev Res (Phila). 2013 Mar;6(3):196-205
pubmed: 23466817
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Dig Liver Dis. 2015 Jan;47(1):37-44
pubmed: 25454708
Cell Prolif. 2014 Aug;47(4):277-86
pubmed: 24909356
Tumour Biol. 2016 Jun;37(6):8007-18
pubmed: 26711784
Int J Mol Sci. 2016 Dec 07;17(12):
pubmed: 27941621
Oncotarget. 2015 Oct 6;6(30):28949-60
pubmed: 26334393
PLoS One. 2016 Sep 01;11(9):e0161967
pubmed: 27583562
J Clin Pathol. 1995 Sep;48(9):876-8
pubmed: 7490328
Surg Endosc. 2002 Feb;16(2):263-6
pubmed: 11967675
World J Gastroenterol. 2008 Feb 21;14(7):1044-52
pubmed: 18286686
Best Pract Res Clin Gastroenterol. 2007;21(6):921-45
pubmed: 18070696
Ann Oncol. 2016 Sep;27(suppl 5):v50-v57
pubmed: 27664261
Carcinogenesis. 2014 Feb;35(2):292-301
pubmed: 24064224
World J Gastroenterol. 2011 Feb 28;17(8):1036-44
pubmed: 21448356
Gene. 2019 Oct 20;716:144025
pubmed: 31394177
Cancer Cell. 2008 Jul 8;14(1):79-89
pubmed: 18598946
Mol Biol Cell. 2008 Nov;19(11):4875-87
pubmed: 18799618
Oncogene. 2007 Oct 25;26(49):6979-88
pubmed: 17486063
Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2237-2242
pubmed: 30670657
Nat Rev Mol Cell Biol. 2000 Nov;1(2):91-100
pubmed: 11253370
Ann Cardiothorac Surg. 2017 Mar;6(2):88-98
pubmed: 28446997
Clin Transl Gastroenterol. 2013 May 16;4:e34
pubmed: 23677165

Auteurs

Daniel Neureiter (D)

Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.
Cancer Cluster Salzburg, 5020 Salzburg, Austria.

Christian Mayr (C)

Department of Internal Medicine I, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.
Institute of Physiology and Pathophysiology, Paracelsus Medical University, 5020 Salzburg, Austria.

Paul Winkelmann (P)

Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.

Bettina Neumayer (B)

Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.

Eckhard Klieser (E)

Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.

Andrej Wagner (A)

Department of Internal Medicine I, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.

Clemens Hufnagl (C)

Institute of Neurointervention, Department of Neurology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.

Klaus Emmanuel (K)

Department of Surgery, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.

Josef Holzinger (J)

Department of Surgery, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.

Oliver Koch (O)

Department of Surgery, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.

Tobias Kiesslich (T)

Department of Internal Medicine I, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.
Institute of Physiology and Pathophysiology, Paracelsus Medical University, 5020 Salzburg, Austria.

Martin Varga (M)

Department of Surgery, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH